BJDX vs. SIENQ, ANZUW, NVACW, NYXH, RCLFW, MEACU, STSSW, MDAIW, STRRP, and STVN
Should you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include Sientra (SIENQ), Anzu Special Acquisition Corp I (ANZUW), NorthView Acquisition (NVACW), Nyxoah (NYXH), Rosecliff Acquisition Corp I (RCLFW), SEP Acquisition (MEACU), Sharps Technology (STSSW), Spectral AI (MDAIW), Star Equity (STRRP), and Stevanato Group (STVN). These companies are all part of the "medical equipment" industry.
Sientra (NASDAQ:SIENQ) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
In the previous week, Bluejay Diagnostics had 2 more articles in the media than Sientra. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 0 mentions for Sientra. Sientra's average media sentiment score of 1.43 beat Bluejay Diagnostics' score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.
Bluejay Diagnostics' return on equity of 0.00% beat Sientra's return on equity.
Bluejay Diagnostics has lower revenue, but higher earnings than Sientra. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.
Sientra has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
17.1% of Sientra shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 1.5% of Sientra shares are owned by insiders. Comparatively, 17.6% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Bluejay Diagnostics received 2 more outperform votes than Sientra when rated by MarketBeat users.
Summary
Bluejay Diagnostics beats Sientra on 7 of the 13 factors compared between the two stocks.
Get Bluejay Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bluejay Diagnostics Competitors List
Related Companies and Tools
